zepbound weight loss - Search News

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

· 1d

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study

· 1d

Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial

· 1d

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

· 22h

First head-to-head trial found Zepbound beats Wegovy for weight loss

· 1d

New study compares Wegovy and Zepbound for the first time

· 1d

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Participants who took Eli Lilly’s tirzepatide, which is sold as Zepbound, lost 50 pounds on average, while those using Novo Nordisk’s semaglutide, also known as Wegovy, lost an average of 33 pounds.

· 1d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 1d

Here’s how much extra weight is lost with Zepbound over Wegovy

23hon MSN

Trump calls out weight-loss drugs as target of price-cut push

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Wellness Companies Eager to Avoid WeightWatchers' Fate Embrace Weight-Loss Drugs

NEW YORK (Reuters) -Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly increased use of the new blockbuster medicines.